‘Translators’ Will Form The Next Generation Of Biopharma Leaders

Interview With 2020 Rising Leader Rabia Khan

Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.

Blue Lightbulbs

Rabia Khan, a geneticist by training with a PhD from McGill University, established early on that she would be a businesswoman not an academic and alongside her PhD, she collected an MBA. Khan was led into the life sciences because of an interest in high school in genetics and “the concept that four letters define who you become and a combination of those four letters determine the massive diversity that we see today.” The human genome had been sequenced at that point and Khan was “fascinated by trying to understand how different combinations of something so simple can lead to such beautiful outcomes.”

After her PhD, Khan started working in a tech company, Meta Inc., where she experienced the benefits of interdisciplinary teams....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.